Coiled Therapeutics (COIL) H2 2025 earnings summary

Executive summary

• Completed strategic pivot from pre-clinical to clinical-stage oncology, acquiring exclusive worldwide rights to AO-252, a first-in-class TACC3 inhibitor in Phase I trials.

• Raised £8.5 million gross via share placing, supporting clinical milestones through 2026–2027.

• Relisted on AIM, changed name to Coiled Therapeutics plc, and restructured Board to align with new clinical focus.

Financial highlights

• Reported a consolidated loss of £3,362,074 for 2025, up from £971,803 in 2024, mainly due to impairment charges and AO-252 acquisition costs.

• Net equity at year-end was £2,419,645 (2024: £4,889,019); closing cash was £78,054 (2024: £337,112).

• Administrative expenses decreased to £683,653 (2024: £931,642); R&D spend was £149,529 (2024: £152,915).

• Net cash outflow for 2025 was £259,623; net cash from financing activities was £386,001.

Outlook and guidance

• Well-funded to reach key AO-252 clinical milestones, with major data readouts expected in H2 2026.

• Plans to initiate dose expansion cohorts in ovarian and prostate cancer, targeting 40 patients by Q3 2026.

• Strategic focus remains on AO-252, with STAT-6 siRNA programme under review for potential Phase I trials or out-licensing.